Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Painless Sharp Wound Debridement With Lidocaine-23%-Tetra-caine-7% Gel Versus EMLA 5% Cream: a Single-blind, Crossover, Randomised, Controlled Trial

NCT05890703 is registered in ClinicalTrials.gov with Juerg Hafner as lead sponsor.

NCT NCT05890703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05890703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Painless Sharp Wound Debridement With Lidocaine-23%-Tetra-caine-7% Gel Versus EMLA 5% Cream: a Single-blind, Crossover, Randomised, Controlled Trial
Lead sponsor
Juerg Hafner
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2023
Completion date
December 31, 2023
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ecthyma, ulcer venous, ulcer, leg, ulcus cruris